

CURRICULUM VITAE

I. PERSONAL HISTORY

Name: Jeffrey Scott Wagener, M.D.
Date and place of birth: (b) (6)
Present position: Professor Emeritus (retired)
Department of Pediatrics
University of Colorado School of Medicine
Present address: (b) (6)
e-mail (university): jeffrey.wagener@ucdenver.edu
Citizenship: USA

II. EDUCATIONAL HISTORY

Kings College, Aberdeen, Scotland,	1968
University of Colorado, Boulder, Colorado	1968-1971
University of Colorado Medical School, Denver, Colorado M.D. (Cum Laude)	1971-1975

Post-graduate Education

Pediatric Intern, Children's Orthopedic Hospital, Seattle, Washington	1975-76
Pediatric Resident, University of Washington, Seattle, Washington	1976-78
Pulmonary Fellow, University of Arizona, Tucson, Arizona	1978-80
Lecturer in Pediatrics, University of Arizona, Tucson, Arizona	1980-81
Lecturer in Pediatrics, University of Melbourne, Melbourne, Australia	1982-83
Sabbatical, Free Radical Research Laboratory, Christchurch School of Medicine, Christchurch, New Zealand	1997
Sabbatical, Consultant Respiratory Paediatrician, Children's University Hospital, Dublin, Ireland	2011

III. LICENSURE

Colorado	#30566	1990-present
Montana	#7359	1993-2005
		2008-2012
Royal College of Physicians, Ireland	#401158	2010-11
Washington	#15468	1976-84
Arizona	#12269	1978-81

Victoria, Australia	Temporary	1982-83
Iowa	#23263	1982-90

IV. BOARD CERTIFICATIONS

National Board of Medical Examiners	#151960	1976
American Board of Pediatrics	#4993	1980
Pediatric Pulmonology	#142	1986-2019
Pediatric Critical Care Medicine	#334	1990-2004

V. PROFESSIONAL POSITIONS

A. Academic Appointments:

University of Iowa, Iowa City, Iowa		
Assistant Professor		1983-88
Associate Professor		1988-90
University of Colorado Medical School, Denver, Colorado		
Associate Professor		1990-97
Professor		1997-2005
Visiting Professor		2005-07
Professor		2007-2013
Professor Emeritus		2013

B. Other Professional Appointments:

Thoracic Paediatrician, Royal Children's Hospital, Melbourne, Australia		1982-83
Associate Director, Cystic Fibrosis Center, University of Iowa		1983-90
Director, Pediatric Pulmonary Physiology Laboratory, U. of Iowa		1984-90
Director, Pediatric Intensive Care, University of Iowa		1985-90
Director, Pulmonary Services, Children's Hospital, Denver, Colorado		1990-2001
Director, Pulmonary Physiology Laboratory, Children's Hospital Denver, Colorado		1990-2005
Associate Director, Cystic Fibrosis Center, University of Colorado Denver, Colorado		1990-2005
Medical Director, Respiratory Care Department, Children's Hospital Denver, Colorado		1995-2004
Medical Director, Biotherapeutics, Genentech, Inc.		2005-07
Director, Pediatric Pulmonary Fellowship, University of Colorado		2007-2012
Consultant Paediatrician, Children's Univ. Hospital, Dublin, Ireland		2010-11
Special Government Employee, Food and Drug Administration		2010-13
Senior Medical Director, Global Medical Affairs, Vertex, Inc.		2013-15

VI. HONORS AND AWARDS

Alpha Omega Alpha National Medical Honor Society	1974
Upjohn Outstanding Junior in Medicine Award	1974
Mosby Outstanding Senior in Medicine Award	1975
Cystic Fibrosis Foundation Clinical Fellowship	1978-80
NIH Pulmonary Research Fellowship	1980-81
Teaching Excellence Award – Pediatrics	1989
Ray Kroc Visiting Professor, University of Kansas	1991
Silver Beaver Award, Boy Scouts of America	1996
American Lung Association of Colorado, Volunteer of the Year	1996
Nicki May Visiting Professor, Royal Children’s Hospital, Melbourne	2004
Outstanding Clinician Award, Colorado Thoracic Society	2008
Outstanding Clinician Award (National), American Thoracic Society	2008
American Pediatric Society	2009
5-Star National Excellence in Healthcare Award	2011
5-Star National Excellence in Healthcare Award	2012
Professor Emeritus	2013
Career Teaching Scholar Award	2014

VII. PROFESSIONAL AFFILIATIONS

American Academy of Pediatrics, Fellow	1980-2009
Scientific Program Committee	1979-80
Pulmonary Section Executive Committee	2001-06
American Lung Association of Colorado Board Member	1993-97
	2001-04
Vice-President	1995-97
CTS Representative	2001-04
American Thoracic Society	1980-2015
Pediatric Section Scientific Program Committee	1986-88
Long Range Planning Committee for Pediatrics	1986-92
Technical Advisory Group on Asthma	1989-95
Manpower Committee	1993-97
Council of Chapter Representatives	2001-06
Secretary	2001-02
Chairperson	2004-05
Scientific Program Committee	2001-04
Board of Directors	2003-06
Clinicians Advisory Committee	2012-15
Colorado Thoracic Society	1991-2013
Chapter Representative	2001-06
Executive Committee	2001-12

Comparative Respiratory Physiology Society	1983-92
Cystic Fibrosis Foundation of Colorado Board Member	1996-2012

VIII. INSTITUTIONAL COMMITTEES

A. Collegiate:

Residency Committee, Department of Pediatrics, U. of Washington	1976-78
Faculty Senate, University of Iowa	1986-87
Faculty Senate, University of Colorado	1991-93
	1996-2004
	2008-2012
Section Heads, Pediatrics, University of Colorado	1991-2001
Clinical Research Center Advisory Committee, University of Colorado	1993-2000
Clinical Practice Committee, Pediatrics, University of Colorado	1996-2002
Colorado Multiple Institutional Review Board, University of Colorado	1999-2002
	2004-06
Graduate Medical Education Committee, University of Colorado	2007-2012
Graduate Medical Education Professionalism Committee, U. of Colo.	2011-12

B. Hospital:

Pediatric Intensive Care Unit Committee, U. of Iowa Hospitals	1984-90
Clinical Affairs Committee, University of Iowa Hospitals	1985-90
Respiratory Therapy Committee, University of Iowa Hospitals	1988-90
Medical Credentials Sub-Committee, University of Iowa Hospitals	1988-90
Critical Care Sub-Committee, University of Iowa Hospitals	1990
Intensive Care Unit Advisory Committee, Children's Hospital	1991-2001
Ambulatory Leadership Team, Children's Hospital, Denver, CO	1993-96
Compensation Committee, Kidsmart, Inc.	1996-2001
Utilization Committee, Kidsmart, Inc.	1999-2001
Hospital Planning and Design Committee, Children's Hospital, Denver	2001-04

C. Other:

Cystic Fibrosis Foundation Center Committee	2002-05
Cystic Fibrosis Foundation Publication Committee	2002-05
Therapeutics Development Network	
Cystic Fibrosis Foundation Steering Committee, EPIC clinical trial	2007-present
Therapeutics Development Network	
Colorado Tobacco Review Committee, State of Colorado	2009-12
Vice-chair	2012
Pediatric Advisory Committee, Food and Drug Administration	2011-13

IX. PATENTS

None

X. REVIEW AND REFEREE WORK

A. Reviewer

American Journal of Disease in Children
American Journal of Respiratory and Critical Care Medicine
Best of Superstuff, (American Lung Association)
Chest
Critical Care Medicine
Current medical literature – Respiratory medicine
European Journal of Pediatrics
European Respiratory Journal
Gastroenterology research and practice
Journal of Pediatrics
Journal of Cystic Fibrosis
Associate Editor 2005-07
Pediatric Pulmonology
Thorax

B. Study Review

Clinical Research Center (Univ. of Iowa)	1988-90
Clinical Research Center (Univ. of Colorado)	1993-2001

C. Consultant

Wisconsin Newborn Lung Project, NIH	1987-89
Genentech, Inc., North American Scientific Advisory Group,	1996-2005
Epidemiologic Study for Cystic Fibrosis	2007-09
	2012-15
Children's Hospital Corporation of America, Pharmacologic Review	1997-98
Committee	
Chiron, Inc., Cystic Fibrosis Advisory Board	2001-05
Gilead, Inc., Cystic Fibrosis Advisory Board	2007-08
Genentech, Inc., Cystic Fibrosis Advisory Board	2007-09
Novartis, Inc., Cystic Fibrosis Advisory Board	2008
GlaxoSmithKlein, Consultant, Cystic Fibrosis	2008
Vertex, Inc., Cystic Fibrosis Advisory Board	2009
International Registries Advisory Board	2012-15
Mpex, Inc., Cystic Fibrosis Advisory Board	2009
Anthera Pharmaceuticals, Liprotomase Study Reviewer	2015

XI. GRANTS AND CONTRACTS

1. Clinical research fellowship 1978-80
National Cystic Fibrosis Foundation
2. Pulmonary function in JRA 1979-80
Principal investigator, Southwest Arthritis Foundation
3. Erythropoiesis in cystic fibrosis 1979-80
Principal Investigator, American Lung Association, Arizona Chapter
4. NIH Research Fellowship Grant #HL-07243 1980-81
5. Laryngotracheobronchitis: A canine model 1980-81
Principal Investigator, American Lung Association, Arizona Chapter
6. Prenatal Unilateral Pulmonary Artery Ligation: Effects on lung growth and development 1985-87
Principal Investigator, American Lung Association
7. Dexamethasone to prevent bronchopulmonary dysplasia 1986-89
Co-investigator, Federal Drug Administration
8. (b) (4) 1986-87
9. Pulmonary diffusing capacity in juvenile diabetics 1987-88
Principle Investigator, Iowa Diabetes Research Fund
10. (b) (4) 1987-88
11. Cystic Fibrosis Center Grant 1991-2005
Co-investigator, Cystic Fibrosis Foundation
12. (b) (4) 1992-93
13. (b) (4) 1992
14. Early pulmonary inflammation in cystic fibrosis 1993-96
Co-investigator, Cystic Fibrosis Foundation
15. (b) (4) 1993
16. (b) (4) 1993
17. Multicenter investigation of non-tuberculous mycobacteria in CF 1994-97
Co-Investigator, Cystic Fibrosis Foundation
18. (b) (4) 1995-96

Curriculum Vitae
 Jeffrey Scott Wagener, MD

- (b) (4)
19. (b) (4) 1995-96
20. (b) (4) 1995-97
21. (b) (4) 1997-99
22. (b) (4) 1997-2005
23. 1998-2001
24. Therapeutics Development Center Grant 1998-2005
 Co-investigator, Cystic Fibrosis Foundation
25. A phase II multicenter randomized trial of tobramycin for inhalation in 2000-01
 young children with cystic fibrosis.
 Co-Investigator, NIH and Cystic Fibrosis Foundation TDN
26. A randomized, double-blinded, placebo-controlled, multicenter study 2000-01
 of the safety and activity of TENOVIL in clinically stable CF subjects.
 Co-investigator, Cystic Fibrosis Foundation TDN
27. (b) (4) 2000-02
28. A phase I/II study of interferon gamma-1b by inhalation for the 2000-02
 treatment of patients with cystic fibrosis.
 Principal Investigator, Cystic Fibrosis Foundation TDN
29. Duration of antimicrobial treatment effect following administration of 2002-04
 Tobramycin for inhalation (TOBI) in young children with cystic fibrosis.
 Principal Investigator, NIH and Cystic Fibrosis Foundation TDN
30. (b) (4) 2002-03
31. Improving Performance of CF Centers in the Detection and 2002-05
 Management of CFRD
 Principal Investigator, Cystic Fibrosis Foundation

32. (b) (4) 2003-05
33. (b) (4) 2004-05
34. (b) (4) 2004-05
35. The EPIC Observational Study: Longitudinal Assessment of Risk Factors for and Impact of *Pseudomonas aeruginosa* Acquisition and Early Anti-Pseudomonal Treatment in Children with CF
Principal Investigator, Cystic Fibrosis Foundation 2004-05
36. (b) (4)
37. Assessment of Induced Sputum as a Tool to Evaluate Anti-inflammatory Agents in Patients with Cystic Fibrosis
Principal Investigator, Cystic Fibrosis Foundation TDN 2005
38. The EPIC Clinical Study: Effectiveness and Safety of Intermittent Antimicrobial Therapy for the Treatment of New Onset *Pseudomonas aeruginosa* Airway Infection in Young Patients with Cystic Fibrosis
Principal Investigator, NIH and Cystic Fibrosis Foundation 2005

XII. SCIENTIFIC INTERESTS

Cystic Fibrosis
Airway Inflammation
Therapeutics development

XIII. BIBLIOGRAPHY

A. Papers Published

1. Wagener JS, Taussig LM, Burrows B, Hernried L, Boat T. Comparison of lung function and survival patterns between cystic fibrosis and emphysema or chronic bronchitis patients, in Sturgess, JM: Perspectives in cystic fibrosis, Ontario, Imperial Press Ltd, Canada, 1980; 236-45.
2. Wagener JS, Taussig LM. Chronic aspiration pneumonitis. Ariz Med 1980; 37:400-2.
3. Wagener JS, Taussig LM, DeBenedetti C, Lemen RJ, Loughlin GM. Pulmonary function in juvenile rheumatoid arthritis. J Pediatr 1981; 99:108-10.
4. Corrigan JJ, Taussig LM, Beckerman R, Wagener JS. Factor II (Prothrombin) coagulant

- activity and immunoreactive protein: Detection of vitamin K deficiency and liver disease in patients with cystic fibrosis. *J Pediatr* 1981; 99:254-7.
5. Wagener JS, Sobonya RE, Taussig LM, Lemen RJ. Unusual abnormalities in adolescent siblings with alpha-1-antitrypsin deficiency. *Chest* 1983; 83:464-68.
 6. Wagener JS, Corrigan JJ, Taussig LM, Lemen RJ. Ferrokinetic and hematologic studies in cystic fibrosis patients. *Am J Pediatr Hematol Oncol* 1983; 5:153-60.
 7. Wagener JS, Minnich L, Sobonya RE, Taussig LM, Ray G, Fulginiti V. Parainfluenza type II infection in dogs: A model for viral lower respiratory tract infection in humans. *Am Rev Respir Dis* 1983; 127:771-5
 8. Sly P, Landau LI, Wagener JS. Acute epiglottitis in childhood: Report of an increased incidence in Victoria. *Aust NZ J Med* 1984; 14:131-4.
 9. Wagener JS, Hibbert M, Landau LI. Maximum respiratory pressures in children. *Am Rev Respir Dis* 1984; 129:873-5.
 10. Wagener JS, Sobonya R, Minnich L, Taussig LM. Role of canine parainfluenza virus and *Bordetella bronchiseptica* in kennel cough. *Am J Vet Res* 1984; 45:1862-7.
 11. Wagener JS, Landau LI, Olinsky A, Phelan PD. Management of children hospitalized for laryngotracheobronchitis. *Pediatr Pulmonol* 1986; 2:159-62.
 12. McCray P, Grandgeorge S, Smith W, Wagener JS, Frey E. Cine CT diagnosis of pulmonary artery sling. *Pediatr Radiol* 1986; 16:508-10.
 13. McCray PB, Wagener JS, Howe CW. Bronchoscopic diagnosis of Cytomegalovirus pneumonia following pediatric bone marrow transplantation. *Am J Pediatr Hematol Oncol* 1986; 8:338-41.
 14. Frey EE, Smith WL, Grandgeorge S, McCray PB, Wagener JS, Franken EA, Sato Y. Chronic airway obstruction in children: Evaluation with cine CT. *Am J Radiol* 1987; 148:347-52.
 15. Harris JB, Lusk R, Wagener JS, Andersen R. Acute viral laryngotracheobronchitis complicated by herpes simplex infection. *J Otolaryn Head Neck Surg* 1987; 96:190-3.
 16. Wagener JS. Fatality following fiberoptic bronchoscopy in a two-year-old child. *Pediatr Pulmonology* 1987; 3:197-9.
 17. Wagener JS, Hendericker C. Intra-subject variability of non-invasive oxygen measurements. *Chest* 1987; 92:1047-9.
 18. McCray P, Crockett D, Wagener JS, Thies DJ. Hypoxia and hypercarbia in infants with mild laryngomalacia. *Am J Dis Child* 1988; 142:896-9.
 19. Humphries CT, Wagener JS, Morgan WJ. Fatal prolonged foreign body aspiration following an asymptomatic interval. *Am J Emerg Med* 1988; 6:611-3.
 20. McCubbin M, Frey EE, Wagener JS, Tribby R, Smith W. Large airway collapse in bronchopulmonary dysplasia. *J Pediatr* 1989; 114:304-7.
 21. Gupta S, Wagener JS, Erenberg A. Pulmonary mechanics in healthy term neonates: Variability in measurements obtained with a computerized system. *J Pediatr* 1990; 117:603-606.
 22. McCubbin MM, Trigg ME, Hendericker CM, Wagener JS. Bronchoscopy with

- bronchoalveolar lavage in the evaluation of pulmonary complications of bone marrow transplantation in children. *Pediatr Pulmonol* 1992; 12:43-7.
23. Mohon RT, Wagener JS, Abman SH, Seltzer WK, Accurso FJ. Relationship of genotype to early pulmonary function in infants with cystic fibrosis identified through neonatal screening. *J Pediatr* 1993; 122:550-5.
 24. Khan TZ, Wagener J, Bost T, Martinez J, Accurso FJ, Riches DWH. Early pulmonary inflammation in infants with cystic fibrosis identified through newborn screening. *Am J Respir Crit Care Med* 1995; 151:1075-82.
 25. Giles DR, Wagener J, Accurso FJ. Acute effects of portural drainage with clapping vs autogenic drainage on oxygen saturation and sputum recovery in patients with cystic fibrosis. *Chest* 1995; 108:952-4.
 26. Petersen MC, Wolraich M, Sherbondy A, Wagener J. Abnormalities in control of ventilation in newborn infants with myelomeningocele. *J Pediatr* 1995; 126:1011-5.
 27. Rothenberg SS, Wagener JS, Chang JHT, Fan LL. The safety and efficacy of thoracoscopic lung biopsy for diagnosis and treatment in infants and children. *J Pediatr Surg* 1995; 31:100-4.
 28. Kirchner KK, Wagener JS, Khan TZ, Accurso FJ. Increased DNA levels in bronchoalveolar lavage fluid obtained from infants with cystic fibrosis. *Am J Respir Crit Care Med* 1996; 154:1246-9.
 29. Fan LL, Lung MC, Wagener JS. The diagnostic value of bronchoalveolar lavage in immunocompetent children with chronic diffuse pulmonary infiltrates. *Pediatr Pulmonol* 1997; 23:8-13.
 30. Rothenberg SS, Bratton D, Larsen G, Deterding R, Milgrom H, Brugman S, Bogenewicz M, Copenhaver S, White C, Wagener J, Fan L, Chang J, Stathos T. Laparoscopic fundoplication to enhance pulmonary function in children with severe reactive airway disease and gastroesophageal reflux disease. *Surg Endosc* 1997; 11:1088-90.
 31. Wagener JS, Rock MJ, McCubbin MN, Hamilton SD, Johnson CA, Ahrens RC. Aerosol delivery and safety of rhDNase in young children with cystic fibrosis: a bronchoscopic study. *J Pediatr* 1998; 133:486-91.
 32. Feranchak AP, Sontag MK, Wagener JS, Hammond KB, Accurso FJ, Sokol RJ. Prospective, long-term study of fat-soluble vitamin status in children with cystic fibrosis identified by newborn screen. *J Pediatr* 1999; 135:601-10.
 33. Rosenfeld M, Emerson J, Accurso F, Armstrong D, Castile R, Grimwood K, Hiatt P, McCoy K, McNamara S, Ramsey B, Wagener J. Diagnostic accuracy of oropharyngeal cultures in infants and young children with cystic fibrosis. *Pediatr Pulmonol* 1999; 28:321-8.
 34. Stern RC, Eisenberg JD, Wagener JS, Ahrens R, Rock M, doPico G, Orenstein DM. A comparison of the efficacy and tolerance of pancrelipase and placebo in the treatment of steatorrhea in cystic fibrosis patients with clinical exocrine pancreatic insufficiency. *Am J Gastroenterology* 2000; 95:1932-8.
 35. Wojtczak HA, Kerby GS, Wagener JS, Copenhaver SC, Gotlin RW, Riches DW et al.

- Beclomethasone dipropionate* reduced airway inflammation without adrenal suppression in young children with cystic fibrosis: a pilot study. *Pediatr Pulmonol* 2001; 32:293-302.
36. Sagel SD, Sontag MK, Wagener JS, Kapsner RK, Osberg I, Accurso FJ. Induced sputum inflammatory measures correlate with lung function in children with cystic fibrosis. *J Pediatr* 2002; 141:811-7.
 37. Maselli JH, Sontag MK, Norris JM, MacKenzie T, Wagener JS, Accurso FJ. Risk factors for initial acquisition of *Pseudomonas aeruginosa* in children with cystic fibrosis identified by newborn screening. *Pediatr Pulmonol* 2003; 35:257-62.
 38. Gibson RL, Emerson J, McNamara S, Burns JL, Rosenfeld M, Yunker A, Hamblett N, Accurso F, Dovey M, Hiatt P, Konstan MW, Moss R, Retsch-Bogart G, Wagener J, Waltz D, Wilmott R, Zeitlin PL, Ramsey B. Significant microbiologic effect of inhaled tobramycin in young children with cystic fibrosis. *Am J Respir Crit Care Med* 2003; 167:841-9.
 39. Konstan MW, Butler SM, Wohl, Stoddard M, Matousek R, Wagener JS, Johnson CA, Morgan WJ. Growth and nutritional indices in early life predict pulmonary function in cystic fibrosis. *J Pediatr* 2003; 142:624-30.
 40. Wooldridge JL, Deutsch GH, Sontag MK, Osberg I, Chase DR, Silkoff PE, Wagener JS, Abman SH, Accurso FJ. NO pathway in CF and non-CF children. *Pediatr Pulmonol* 2004; 37:338-50.
 41. Konstan MW, Stern RC, Sherman JM, Eigan H, Wagener JS, Duggan C, Colin P. Ultrase MT12 and Ultrase MT20 in the treatment of exocrine pancreatic insufficiency in cystic fibrosis: safety and efficacy. *Aliment Pharmacol Ther* 2004; 20:1365-71.
 42. Konstan MW, Davis PB, Wagener JS, Hilliard KA, Stern RC, Milgram LJH, Kowalczyk TH, Hyatt SL, Fink TL, Gedeon CR, Oette SM, Payne JM, Muhammad O, Ziady AG, Moen RC, Cooper MJ. Compacted DNA nanoparticles administered to the nasal mucosa of cystic fibrosis subjects are safe and demonstrate partial to complete CFTR reconstitution. *Human Gene Therapy* 2004; 15:1255-69.
 43. Kettle AJ, Chan T, Osberg I, Senthilmohan R, Chapman ALP, Mocatta TJ, Wagener JS. Myeloperoxidase and protein oxidation in the airways of young children with cystic fibrosis. *Am J Respir Crit Care Med* 2004; 170:1317-23.
 44. Accurso FJ, Sontag, MK, Wagener JS. Complications associated with symptomatic diagnosis in infants with cystic fibrosis. *J Pediatr* 2005; 147:S37-41.
 45. Sontag MK, Hammond KB, Zielinski J, Wagener JS, Accurso FJ. Two-tiered immunoreactive trypsinogen-based newborn screening for cystic fibrosis in Colorado: screening efficacy and diagnostic outcomes. *J Pediatr* 2005; 147:S83-8.
 46. Rodman DM, Polis JM, Heltshe S, Sontag MK, Chacon C, Rodman RV, Brayshaw SJ, Huitt GA, Iseman MD, Saavedra MT, Taussig LM, Wagener JS, Accurso FJ, Nick JA. Late diagnosis defines a unique population of long-term survivors of cystic fibrosis. *Am J Respir Crit Care Med*. 2005 Mar 15; 171:621-6.
 47. Moss RB, Mayer-Hamblett N, Wagener J, Daines C, Hale K, Ahrens R, Gibson RL, Andersen P, Retsch-Bogart G, Nasr SZ, Noth I, Waltz D, Zeitlin P, Ramsey B, Starko K.

- A randomized, double blind, placebo controlled, dose escalating study of aerosolized interferon gamma 1b in patients with mild to moderate cystic fibrosis lung disease. *Pediatr Pulmonol* 2005; 39:209-18.
48. McMullen A, Pasta D, Fredrick P, Wagener JS. Impact of pregnancy on women with cystic fibrosis. *Chest* 2006; 129:706-11.
 49. Borowitz D, Goss CH, Stevens C, Hays D, Newman L, O'Rourke A, Konstan MW, Wagener J, Moss R, Hendeles L, Orenstein D, Ahrens R, Oermann CM, Aitken ML, Mahl TC, Young KR Jr, Dunitz J, Murray FT. Safety and preliminary clinical activity of a novel pancreatic enzyme preparation in pancreatic insufficient cystic fibrosis patients. *Pancreas* 2006; 32:258-63.
 50. Padman R, McColley SA, Miller DP, Konstan MW, Morgan WJ, Schechter MS, Ren CL, Wagener JS. Infant care patterns at epidemiologic study of cystic fibrosis sites that achieve superior childhood lung function. *Pediatrics* 2007; 119:531-7.
 51. Ren CL, Morgan WJ, Konstan MW, Wagener JS, Cheeks ME, Fisher KA, Regelmann WE. Relationship between methicillin resistant staphylococcus aureus in cystic fibrosis respiratory cultures and clinical status. *Pediatr Pulmonol* 2007; 42:513-8.
 52. Konstan MW, Morgan WJ, Butler SM, Pasta DJ, Craib ML, Silve SJ, Stokes D, Wohl MEB, Wagener JS, Regelmann WE, Johnson CA. Risk factors for rate of decline in FEV1 in children and adolescents with cystic fibrosis. *J Pediatr* 2007; 151:134-9.
 53. Papas KA, Sontag MK, Pardee C, Sokol RJ, Sagel SD, Accurso FJ, Wagener JS. A pilot study on the safety and efficacy of a novel antioxidant rich formulation in patients with cystic fibrosis. *J Cystic Fibrosis* 2008; 7:60-7.
 54. Laguna TA, Sontag MK, Osberg I, Wagener JS, Accurso FJ, Sokol RJ. Decreased total serum coenzyme Q10 concentrations: a longitudinal study in children with cystic fibrosis. *J Pediatrics* 2008; 153:402-7.
 55. VanDevanter DR, Rasouliyan L, Murphy TM, Morgan WJ, Ren CL, Konstan MW, Wagener JW. Trends in the clinical characteristics of the U.S. cystic fibrosis patient population from 1995 to 2005. *Pediatr Pulmonol* 2008; 43:739-44.
 56. Moskowitz SM, Silva SJ, Mayer-Hamblett N, Pasta DJ, Mink DR, Wagener JS, Konstan MW, Ramsey BW, Morgan WJ. Shifting patterns of inhaled antibiotic use in cystic fibrosis. *Pediatr Pulmonol* 2008; 43:874-81.
 57. Ren CL, Pasta DJ, Rasouliyan L, Wagener JS, Konstan MS, Morgan WJ. Relationship between inhaled corticosteroid therapy and rate of lung function decline in children with cystic fibrosis. *J Pediatrics* 2008; 153:746-51.
 58. Sawicki GS, Rasouliyan L, Pasta DJ, Regelmann WE, Wagener JS, Waltz DA, Ren CL. The impact of incident methicillin resistant *Staphylococcus aureus* detection on pulmonary function in cystic fibrosis. *Pediatr Pulmonol* 2008; 43:1117-23.
 59. Sagel SD, Gibson RL, Emerson J, McNamara S, Burns JL, Wagener JS, Ramsey BW. Impact of pseudomonas and Staphylococcus infection on inflammation and clinical status in young children with cystic fibrosis. *J Pediatr* 2009; 154:183-8.
 60. Schechter MS, McColley SA, Silva S, Haselkorn T, Konstan MW, Wagener JS.

- Association of socioeconomic status with the use of chronic therapies and healthcare utilization in children with cystic fibrosis. *J Pediatr* 2009; 155:634-9.
61. Quittner AL, Schechter MS, Rasouliyan L, Pasta D, Wagener JS. Impact of socioeconomic status, race, and ethnicity on quality of life in patients with cystic fibrosis: analyses of a national database. *Chest* 2010;137:642-50.
 62. Zemanick ET, Wagner BD, Harris JK, Wagener JS, Accurso FJ, Sagel SD. Pulmonary exacerbations in cystic fibrosis with negative bacterial cultures. *Pediatr Pulmonol* 2010;45:569-77.
 63. Liou TG, Elkin EP, Pasta DJ, Jacobs JR, Konstan MW, Morgan WJ, Wagener JS. Year-to-year changes in lung function in individuals with cystic fibrosis. *J Cyst Fibros* 2010;9:250-6.
 64. Konstan M, VanDevanter D, Rasouliyan L, Pasta D, Yegin A, Morgan W, Wagener J. Trends in the use of routine therapies in cystic fibrosis: 1995-2005. *Pediatr Pulmonol* 2010;45:1167-72.
 65. VanDevanter DR, Wagener JS, Pasta DJ, Elkin E, Jacobs JR, Morgan WJ, Konstan MW. Pulmonary outcome prediction (POP) tools for cystic fibrosis patients. *Pediatr Pulmonol* 2010;45:1156-66.
 66. Konstan MS, Wagener JS, Yegin A, Millar SJ, Pasta DJ, VanDevanter DR. Design and powering of cystic fibrosis clinical trials using rate of FEV1 decline as an efficacy endpoint. *J Cyst Fibros* 2010;9:332-8.
 67. Sawicki GS, Rasouliyan L, McMullen AH, Wagener JS, McColley SA, Pasta DJ, Quittner AL. Longitudinal assessment of health-related quality of life in an observational cohort of patients with cystic fibrosis. *Pediatr Pulmonol* 2011;46:36-44.
 68. Shah SS, Hall M, Newland JG, Brogan TV, Farris RW, Williams DJ, Larsen G, Fine BR, Levin JE, Wagener JS, Conway PH, Myers AL. Comparative effectiveness of pleural drainage procedures for the treatment of complicated pneumonia in childhood. *J Hosp Med* 2011;6:545-53.
 69. Konstan MW, Wagener JS, Pasta DJ, Millar SJ, Jacobs JR, Yegin A, Morgan WJ. Clinical use of dornase alfa is associated with a slower rate of FEV1 decline in chstic fibrosis. *Pediatr Pulmonol* 2011;46:545-53.
 70. Schechter MS, McColley SA, Regelman W, Millar SJ, Pasta DJ, Wagener JS, Konstan MW, Morgan WJ. Socioeconomic status and the likelihood of antibiotic treatment for signs and symptoms of pulmonary exacerbation in children with cystic fibrosis. *J Pediatr* 2011;159:819-24.
 71. VandenBranden SL, McMullen A, Schechter MS, Pasta DJ, Michaelis RL, Konstan MW, Wagener JS, Morgan WJ, McColley SA. Lung function decline from adolescence to young adulthood in cystic fibrosis. *Pediatr Pulmonol* 2012; 47:135-43.
 72. Konstan MW, Wagener JS, Vandevanter DR, Pasta DJ, Yegin A, Rasouliyan L, Morgan WJ. Risk factors for rate of decline in FEV₁ in adults with cystic fibrosis. *J Cyst Fibros* 2012;11:405-11.
 73. Wagener JS, Rasouliyan L, Vandevanter DR, Pasta DJ, Regelmenn WE, Morgan WJ,

- Konstan MW. Oral, inhaled, and intravenous antibiotic choice for treating pulmonary exacerbations in cystic fibrosis. *Pediatr Pulmonol* 2013;48:666-73.
74. Regelmann WE, Schechter MS, Wagener JS, Morgan WJ, Pasta DJ, Elkin EP, Konstan MW. Pulmonary exacerbations in cystic fibrosis: Young children with characteristic signs and symptoms. *Pediatr Pulmonol* 2013;48:649-57.
75. Morgan WJ, Wagener JS, Yegin A, Pasta DJ, Millar SJ, Konstan MW. Probability of treatment following acute decline in lung function in children with cystic fibrosis is related to baseline pulmonary function. *J Pediatr* 2013;163:1152-7.
76. Mayer-Hamblett N, Rosenfeld M, Treggiari MM, Konstan MW, Retsch-Bogart G, Morgan W, Wagener J, Gibson RL, Khan U, Emerson J, Thompson V, Elkin EP, Ramsey BW. Standard care versus protocol based therapy for new onset *Pseudomonas aeruginosa* in cystic fibrosis. *Pediatr Pulmonol* 2013;48:943-53.
77. Kupfer O, Ridall LA, Hoffman LM, Dishop MK, Soep JB, Wagener JS, Fan LL. Pulmonary capillaritis in monozygotic twin boys. *Pediatrics* 2013;132:e1445-8.
78. Konstan MW, Wagener JS, Pasta DJ, Millar SJ, Morgan WJ. Clinical use of tobramycin inhalation solution (TOBI[®]) shows sustained improvement in FEV₁ in cystic fibrosis. *Pediatr Pulmonol* 2014;49:529-36.
79. Wagener JS, Woo MS, Pasta DJ, Konstan MW, Morgan WJ. Liver involvement in the Hispanic population of North America with cystic fibrosis. *J Pediatr Gastroenterol Nutr* 2014;59:476-9.
80. Wagener JS, Elkin EP, Pasta DJ, Schechter MS, Konstan MW, Morgan WJ. Pulmonary function outcomes for assessing cystic fibrosis care. *J Cyst Fibros* 2015;14:376-83.
81. Sawicki GS, McKone EF, Pasta DJ, Millar SJ, Wagener JS, Johnson CA, Konstan MW. Sustained benefit from ivacaftor demonstrated by combining clinical trial and CF patient registry data. *Am J Respir Crit Care Med* 2015;192:836-42.
82. Morgan WJ, VanDevanter DR, Pasta DJ, Foreman AJ, Wagener JS, Konstan MW. Forced expiratory volume in 1 second variability helps identify patients with cystic fibrosis at risk of greater loss of lung function. *J Pediatr* 2016;169:116-21.
83. Liou TG, Jensen JL, Allen SE, Brayshaw SJ, Brown MA, Chatfield B, McDonald C, Koenig J, Packer KA, Peet K, Radford P, Reineke L, Otsuka K, Wagener JS, Young D, Marshall BC. Improving performance in the detection and management of cystic fibrosis related diabetes in the Mountain West Cystic Fibrosis Consortium. *BMJ Open Diabetes Research and Care* 2016;4:e000183.
84. Suthoff ED, Bonafede M, Limone B, O'Callaghan L, Sawicki GS, Wagener JS. Healthcare resource utilization associated with ivacaftor use in patients with cystic fibrosis. *J Med Econ* 2016.

B. Book Chapters

1. Wagener JS, Taussig LM. Cystic Fibrosis. In: *Current Therapy for Respiratory Disease*, Cherniack RM ed., BC Decker Inc., 1984; pp. 158-166.

2. Wagener JS, Taussig LM. Cystic Fibrosis. In: *Current Therapy in Internal Medicine*, Bayless TM, Brain MC, and Cherniack RM Eds., BC Decker Inc., 1984; pp. 822-830.
3. Larsen GL, Abman SH, Fan LL, Wagener JS, White CW, Accurso FJ. Respiratory track and mediastinum. In: *Current Pediatric Diagnosis and Treatment*, Hay, Groothuis, Hayward, Levin eds., Lange, 1997; pp.428-73.
4. Wojtczak HA, Wagener JS. Corticosteroids in pediatric asthma. In: *The Pediatric Lung*, Wilmott RW ed., Birkhauser Ltd, Basel, 1997; pp. 41-82.
5. Wagener JS, Deterding R. Alveolar proteinosis. In: *Textbook of Pediatric Respiratory Medicine*, Taussig LM, Landau LI eds., Mosby, 1999; pp. 830-4.
6. Wagener JS. Hollister JR, Hay TC. Collagen vascular disorders. In: *Textbook of Pediatric Respiratory Medicine*, Taussig LM, Landau LI eds., Mosby, 1999; pp. 818-29.
7. Lazarus RA, Wagener JS. Recombinant Human Deoxyribonuclease I. In *Pharmaceutical Biotechnology*, 3rd ed., Crommelin DJA, Sindelar RD, and Meibohm B, eds., Informa Healthcare USA Inc., New York, Ch. 19, 2007; pp. 387-398.
8. Wagener JS, Deterding R. Alveolar proteinosis. In: *Textbook of Pediatric Respiratory Medicine*, Taussig LM, Landau LI eds., Mosby, 2008; pp. 705-10.
9. Wagener JS, Soap J, Hay TC. Collagen vascular disorders. In: *Textbook of Pediatric Respiratory Medicine*, Taussig LM, Landau LI eds., Mosby, 2008; pp. 693-704.
10. Wagener JS. Pneumonia. In: *Berman's Pediatric Decision Making*, Bajaj, Hambidge, Kerby, Nyquist eds., Elsevier, 2011;pp. 754-9.
11. Wagener JS. Parapneumonic effusion and empyema. In: *Clinical Decision Support*, Jones ed., 2011.
12. Lazarus RA, Wagener JS. Recombinant Human Deoxyribonuclease I. In *Pharmaceutical Biotechnology*, 4th ed., Crommelin DJA, Sindelar RD, and Meibohm B, eds., Informa Healthcare USA Inc., New York, 2013.
13. Wagener JS, Kupfer O. Parapneumonic effusion and empyema. In: *Clinical Decision Support*, Jones ed., 2016.

C. Editorials and Scholarly Reviews

1. Wagener JS. Bronchopulmonary Dysplasia. Newborn Follow-up 1979; 3:3-4.
2. Wagener JS. Respiratory emergencies: Managing upper airway obstruction in children. Consultant 1984; 24:115-23.
3. Wagener JS. Respiratory distress: Exploring the causes in young children. Consultant 1986; 26:23-37.
4. Long range planning committee for pediatric pulmonology. Pediatric pulmonology 1985 manpower study. Pediatrics 1988; 81:680-3.
5. American Thoracic Society pulmonary and critical care training committee. Role of the pulmonary and critical care medicine physician in the American health care system. Am J Respir Crit Care Med 1995; 152:2199-2201.
6. Wagener JS. Anti-inflammatory therapy of asthma in children. Current Opinions Pediatr

- 1995; 7:262-7.
7. Accurso FJ, Khan TZ, Wagener JS, Copenhaver SC, Kirchner KK. Does inflammation precede infection in early airways disease in cystic fibrosis. *Pediatr Pulmonol* 1995; Suppl 12:71-2.
 8. Wagener JS, Copenhaver SC, Kirchner KK, Accurso FJ. Early pulmonary treatment in cystic fibrosis. *Pediatr Pulmonology* 1995; Suppl 12:84-5.
 9. Wagener JS, Erskine JM, Krebs NF, Sokol RJ, Accurso FJ. Airway inflammation and nutritional status in young children with cystic fibrosis. *Pediatr Pulmonol* 1996; Suppl 13:161-2.
 10. American Thoracic Society pulmonary and critical care training committee. The role of the pediatric pulmonary physician in the American health care system. *Am J Respir Crit Care Med* 1997; 155:1486-8.
 11. Accurso FJ, Sontag MK, Wagener JS. Newborn screening for cystic fibrosis: The need from a center director's standpoint. *Pediatr Pulmonol* 1997; Suppl 14:188-9.
 12. Wagener JS, Kahn TZ, Copenhaver SC, Accurso FJ. Early inflammation and the development of pulmonary disease in cystic fibrosis. *Pediatr Pulmonol* 1997; Suppl 16:267-8.
 13. Accurso FJ, Wagener JS, Sontag MK. The role of early diagnosis and treatment in the development of the cystic fibrosis phenotype. *Pediatr Pulmonol* 1998; Suppl 17:98-99.
 14. Wagener JS, Wojtczak HA. Inhaled steroids in children: Risks vs. Rewards. *J Pediatr* 1998; 132:381-3 (Editorial).
 15. Schidlow D, Butler S, Johnson C, Rao A, Wagener J, Regelman W, Morgan. Predictors of progression to severe pulmonary status in cystic fibrosis. *Pediatr Pulmonol* 1998; Suppl 17:149-51.
 16. Accurso FJ, Wagener JS, Sontag MK. The role of early diagnosis and treatment in the development of the Cystic Fibrosis phenotype. *Pediatr Pulmonol* 1998; Suppl 17:98-9.
 17. Wagener J, Butler S, Rabin H, Regelman W, Johnson C. New cases of *Pseudomonas aeruginosa*: Risk factors and outcomes. *Pediatr Pulmonol* 1998; Suppl 17:147-8.
 18. Schidlow D, Butler S, Johnson C, Rao A, Wagener J, Regelman W, Morgan W. Predictors of progression to severe pulmonary status in cystic fibrosis. *Pediatr Pulmonol* 1998; Suppl 17:149-51.
 19. Wojtczak HA, Sontag MK, Wagener JS, Accurso FJ. Inhaled corticosteroid treatment in infants and young children with cystic fibrosis. *Pediatr Pulmonol* 1999; Suppl 19:105-6.
 20. Konstan MW, Butler SM, Johnson CA, Wagener JS, Lai HC, Morgan WJ. The relationship between nutritional status in early life and pulmonary function in cystic fibrosis. *Pediatr Pulmonol* 1999; Suppl 19:155-6.
 21. Wagener JS, Butler SM, Rabin H, Regelman W, Johnson C. New cases of *Pseudomonas aeruginosa*: Treatment and outcomes. *Pediatr Pulmonol* 1999; Suppl 19:158-9.
 22. Wagener JS, Sontag MK, and Accurso FJ. Prevalence of *Pseudomonas aeruginosa* in children with cystic fibrosis detected by neonatal screening. In: *Neonatal Screening for Cystic Fibrosis*, Caen Cedex, France:Presses Universitaires de Caen, 1999, p. 199-207.

23. Sontag MK, Hammond K, Wagener JS, Accurso FJ. Maturation of sweat chloride and sodium in young children with early diagnosis of cystic fibrosis in Colorado. In: *Neonatal Screening for Cystic Fibrosis*, Caen Cedex, France:Presses Universitaires de Caen, 1999, p. 91-95.
24. Accurso FJ, Wagener JS, Sontag MK, Hammond KB. Strategies for effective early clinical intervention in cystic fibrosis. In: *Neonatal Screening for Cystic Fibrosis*, Caen Cedex, France:Presses Universitaires de Caen, 1999, p. 199-207.
25. Deterding RM and Wagener JS. Open lung biopsy: Who, when, and why. *J Pediatr* 2000; 147:9 (Editorial).
26. Balasubramaniam V and Wagener JS. Kendig's *Disorders of the respiratory tract in children*. *Respir Care* 2001; 46:68-9 (Book review).
27. Jones M and Wagener JS. Managing acute pediatric asthma. Keeping it short. *J Pediatr* 2001; 139:3-5 (Editorial).
28. Wagener JS, Farrell PM, Corey M. Why my state (province) should conduct newborn screening for cystic fibrosis. *Pediatr Pulmonol* 2001; 32:385-96 (Commentary).
29. American Academy of Pediatrics section on pediatric pulmonology. Clinical practice guideline: Diagnosis and management of childhood obstructive sleep apnea syndrome. *Pediatrics* 2002; 109:704-12.
30. Wagener JS, Sontag MK, Accurso FJ. Newborn screening for cystic fibrosis. *Curr Opin Pediatr* 2003; 15:309-15.
31. Wagener JS, Headley A. Respiratory therapy in cystic fibrosis. *Respiratory Care* 2003; 48:234-45.
32. Wagener JS, Sontag MK, Sagel SD, Accurso FJ. Update on newborn screening for cystic fibrosis. *Curr Opin Pulm Med* 2004; 10:500-4.
33. Konstan MW, Wagener JS, VanDevanter DR. Characterizing aggressiveness and predicting future progression of CF lung disease. *J Cyst Fibros* 2009;8:S15-9.
34. Wagener JS, Zemanick ET, Sontag MK. Newborn screening for cystic fibrosis. *Curr Opin Pediatr* 2012; 24:329-35.
35. Wagener JS, Kupfer O. Dornase alfa (Pulmozyme). *Curr Opin Pulm Med* 2012;18:609-14.

D. Audiovisual Publications

1. Wagener JS, Accurso FJ. Early lung disease in cystic fibrosis. SynerMed 1996 (slide presentation).
2. Wagener JS. Go for your goal. Ketchum Public Relations 1996, (audiovisual presentation).
3. Wagener JS. Pulmozyme therapy in under 5-year old children with cystic fibrosis. SynerMed, 1998 (slide presentation).
4. Wagener JS. Treating the under 5-year old child with cystic fibrosis. Ketchum Public Relations, 1998 (audiovisual presentation).
5. Wagener JS, Konstan M. Early aggressive treatment of cystic fibrosis. Medpoint, 2002 (internet presentations).

E. Letters to the Editor

1. Wagener JS, Taussig LM, and Corrigan JJ. Cystic Fibrosis study questioned. *Pediatrics* 1984; 74:169.
2. Wagener JS. Questions on emergency respiratory distress. *Consultant* 1986; 26:133.
3. Grandgeorge S, Wagener JS. Follicular bronchiectasis. *Pediatr Pulmonol* 1987; 3:282.
4. Wagener JS. Questions on bronchoscopy. *Pediatr Pulmonol* 1988.
5. Wagener JS. What is in a meeting? *CF Update* 1990; 7:4.
6. Schechter MS, Wagener J, Konstan MW, Morgan W. Location and duration of treatment of cystic fibrosis respiratory exacerbations. *Am J Respir Crit Care Med* 2011;184:278.

F. Abstracts (presented)

1. Wagener JS, Taussig LM, Corrigan JJ, and Lemen RJ. Erythropoietin levels in patients with cystic fibrosis. Cystic Fibrosis Club, April 1979.
2. Wagener JS, Taussig LM, Burrows B, Hernried L, Boat T. Comparison of lung function and survival patterns between cystic fibrosis and emphysema or chronic bronchitis patients. American Thoracic Society, May 1980.
3. Allen HD, Lemen RJ, Revsin-Lanier B, Wagener J. Abnormal pulmonary prostaglandin metabolism in cystic fibrosis. American Heart Association, November 1980.
4. Wagener JS, Minnich L, Sobonya R, Ray G, McKelvie D, Fulginitti V, Taussig L. Kennel cough: A canine model for viral airway disease. American Thoracic Society, May 1981.
5. Wagener J, Sobonya R, Taussig L, Lemen R. Pulmonary anatomic abnormalities in alpha-I-antitrypsin deficient adolescents. American College of Chest Physicians, October 1981.
6. Prussak CE, Wagener J, Taussig LM, Brendel K. Cystic fibrosis patients excrete elevated amounts of the acetylated polyamines. Western Pharmacology Society, 1983.
7. Wagener JS, Sobonya R, Minnich L, Taussig LM. Role of canine parainfluenza virus and *Bordetella bronchiseptica* in producing kennel cough. Third Veterinary Respiratory Symposium, October 1983.
8. Lusk R, Harris JB, Wagener JS, Anderson R. Herpes simplex laryngotracheitis. American Academy of Otolaryngology, September 1984.
9. Humphries CT, Ellerbroek C, Wagener JS, Florentine M, Smith W. Radiographic complications following repair of congenital heart defects. American Academy of Pediatrics, October 1985.
10. Hendricker C, Wagener JS. Inpatient variability of non-invasive oxygen measurements. *Chest*, 1985.
11. Frey E, Smith W, Wagener J, Grandgeorge S, Franken E, McCray P. Evaluation of chronic pediatric airway obstruction with Cine CT. Society for Pediatric Radiology, March 1986.
12. Wagener JS, Pringle K. Lung growth and development following intrauterine unilateral

- pulmonary artery occlusion. American Thoracic Society, May 1986.
13. Frey EE, Smith WL, Franken EA, Wagener JS, Sato Y. Vascular rings with tracheal and esophageal compression identification by Cine CT. European Society for Pediatric Radiology, May 1986.
 14. McCubbin MM, Frey EE, Wagener JS, Tribby RE, Smith W. Tracheobronchomalacia in patients with bronchopulmonary dysplasia. Society for Pediatric Research, April 1987.
 15. Parks D, Rodgers P, Wagener JS, Ruffin T. New technique for measuring gas diffusion in children. American Thoracic Society, May 1987.
 16. McCray P, Crockett D, Wagener JS, and Thies D. The incidence of hypoxia and hypercarbia in infants with laryngomalacia. American Thoracic Society, May 1987.
 17. Gupta S, Johnson K, Hendricker C, Thies D, Wagener J, Erenberg A. Variability in measurements of pulmonary mechanics in healthy term neonates. Midwest Society for Pediatric Research, November 1988.
 18. Sato Y, Kao SCS, Wagener JS, Smith W, Franken EA. Neonatal tracheomegaly: Cine CT evaluation. Radiologic Society of North America, November 1988.
 19. McCubbin M, Hendricker C, Ahrens R, Trigg M, Wagener J. Flexible bronchoscopy and bronchoalveolar lavage (BAL) in the evaluation of pulmonary complications of pediatric bone marrow transplant (BMT) recipients. American Thoracic Society, May 1990.
 20. Gupta S, Hendricker C, Thies D, Powlis K, Wagener J, Erenberg A. Variability in measurements of pulmonary mechanics in patients with bronchopulmonary dysplasia. Society for Pediatric Research, April 1990.
 21. Wagener J, Pringle K. Effects of Prenatal Unilateral Pulmonary Artery Ligation on Intrauterine Growth. American Physiological Society, October 1990.
 22. Kao CS, Wagener JS, Smith WL, Sato Y, Franken EA, Trigg ME. Chest radiography in symptomatic children after bone marrow transplantation. Radiological Society of North America, 1990.
 23. Mohon RT, Abman SH, Wagener JS, Accurso FJ. Pulmonary function and bronchodilator responsiveness in asymptomatic infants with cystic fibrosis diagnosed through newborn screening. American Thoracic Society, 1991.
 24. Mohon RT, Wagener JS, Accurso FJ, Abman SH. Early pulmonary function and bronchodilator responsiveness in infants with cystic fibrosis diagnosed through newborn screening. *Pediatr Pulmonol* 1991; Suppl 10.
 25. Khan TZ, Wagener JS, Riches DWH, Accurso FJ. Increased interleukin-8 levels and gene expression by pulmonary macrophages in bronchoalveolar lavage fluid from infants with cystic fibrosis. Western Society for Pediatric Research, 1993.
 26. Khan TZ, Wagener JS, Riches DWH, Accurso FJ. Increased interleukin-8 levels and gene expression by pulmonary macrophages in bronchoalveolar lavage fluid from infants with cystic fibrosis. American Thoracic Society, 1993.
 27. Kirchner KK, Khan TZ, Wagener JS, Accurso FJ. Increased DNA levels in bronchoalveolar lavage fluid obtained from infants with cystic fibrosis. *Pediatr Pulmonol* 1993; Suppl 12.

28. Khan TZ, Copenhaver SC, Kirchner KK, Wagener JS, Carroll NM, Accurso FJ. Serial assessment of airway inflammation in infants with cystic fibrosis identified through newborn screening. *Pediatr Pulmonol* 1994; Suppl 13.
29. Accurso FJ, Wagener JS, Abman SH, Sokol RJ, Carroll NM. Growth and pulmonary function outcome in children with cystic fibrosis identified through newborn screening. *Pediatr Pulmonol* 1994; Suppl 13.
30. Sokol RJ, Narkewicz MR, Carroll NM, Wagener JS. Prospective evaluation of liver blood tests during the first 8 years of life in children with cystic fibrosis identified by newborn screening. American Association for the Study of Liver Diseases, 1994.
31. Butler-Simon N, McCool P, Giles D, Pritts J, Accurso F, Wagener JS. Efficacy and desirability of autogenic drainage vs. conventional postural drainage and percussion. *Pediatr Pulmonol* 1995; Suppl 14.
32. Wojtczak HA, Wagener JS, Accurso FA. Inhaled steroid effects on airway inflammation in children with cystic fibrosis. International Cystic Fibrosis Conference, 1996.
33. Accurso F, Ahrens R, Birrer P, Eigen H, Johnson C, Kirchner K, McCubbin M, Nickerson B, Palazzo R, Rock M, Wagener JS. Deposition of aerosolized rhDNase in infants and children with cystic fibrosis. International Cystic Fibrosis Conference, 1996.
34. Rock M, Kirchner K, McCubbin M, Accurso F, Ahrens R, Birrer P, Eigen H, Johnson C, Nickerson B, Palazzo R, Wagener JS. Aerosol delivery and safety of rhDNase in young children with cystic fibrosis: A bronchoscopic study. *Pediatr Pulmonol* 1996; Suppl 15.
35. McCubbin MM, Kircher K, Ahrens R, Rock M, Accurso F, Nickerson B, Palazzo R, Birrer P, Eigen H, Wagener JS. Bronchoscopy with BAL detects early inflammation and infection in young CF patients: A multicenter study. *Pediatr Pulmonol* 1996; Suppl 15.
36. Eichner J, Hay T, Sontag M, Wagener JS, Accurso F. Comparison of the Brasfield and Wisconsin chest radiograph scoring systems for detecting lung disease progression in infants and children with cystic fibrosis identified by newborn screening. *Pediatr Pulmonol* 1996; Suppl 15.
37. Giles D, Sontag M, Wagener J, Accurso F. Effect of one month of treatment with flutter valve or postural drainage and clapping on pulmonary function and sputum recovery in cystic fibrosis. *Pediatr Pulmonol* 1996; Suppl 15.
38. Wojtczak HA, Wagener JS, Kerby G, Gotlin R, Accurso F. Effect of inhaled beclomethasone dipropionate on airway inflammation in children with cystic fibrosis. *Pediatr Pulmonol* 1996; Suppl 15.
39. Rosenfeld M, Emerson J, Accurso F, Armstrong D, Castile R, Grimwood K, Hiatt P, McCoy K, McNamara S, Ramsey B, Wagener JS. Diagnostic accuracy of oropharyngeal cultures relative to lower airway cultures in infants and young children with cystic fibrosis. *Pediatr Pulmonol* 1997; Suppl 16.
40. Wagener JS, Sontag MK, Accurso FJ. Long term stability of airway inflammation in infants and young children with cystic fibrosis. *Pediatr Pulmonol* 1997; Suppl 16.
41. Wagener JS, Kettle A. Myeloperoxidase in bronchoalveolar lavage fluid obtained from infants and young children with cystic fibrosis. *Pediatr Pulmonol* 1997; Suppl 16.

42. Sontag MK, Hammond KB, Wagener JS, Accurso FJ. Maturation of sweat chloride and sodium in young children with early diagnosis of cystic fibrosis in Colorado. *Pediatr Pulmonol* 1998; Suppl 17:252.
43. Accurso FJ, Sontag MK, Wagener JS, Hammond KB. Cystic Fibrosis in infants with persistent hypertrypsinogenemia and “Borderline” sweat tests. *Pediatr Pulmonol* 1998; Suppl 17:292.
44. Wojtczak HA, Wagener JS, Sontag MK, Accurso FJ. Bronchoalveolar lavage assessment of airway delivery of Fluticasone propionate via pressurized metered dose inhaler in infants and young children with cystic fibrosis. *Pediatr Pulmonol* 1998; Suppl 17:341.
45. Accurso FJ, Sontag MK, Wagener JS. Relationship of bronchoalveolar lavage levels and antimicrobial proteins to airway inflammation in cystic fibrosis. *Pediatr Pulmonol* 1998; Suppl 17:388.
46. Wagener J, Butler S, Stoddard M, Zheng B, Regelman W, Konstan M, Morgan W. Age related risk factors for new detection of *Pseudomonas aeruginosa*. *Pediatr Pulmonol* 2001; Suppl.
47. Senthilomohan R, Mocatta T, Buss H, Darlow B, Wagener J, Kettle A, Winterbourn C. Oxidative modification of protein in cystic fibrosis patients and in chronic lung disease of preterm infants. *Free Radical Biology and Med* 2001; 31 Suppl 1:S89.
48. Wooldridge JL, Deutsch G, Osberg I, Sontag MK, Wagener JS, Accurso FJ. Expression of type II nitric oxide synthase in airway epithelial cells in children with cystic fibrosis. *Am J Respir Crit Care Med* 2002; 165:A279.
49. Sagel S, Kapsner R, Osberg I, Sontag M, Wagener J, Accurso F. Induced sputum inflammatory measures correlate with lung function in children with cystic fibrosis. *Am J Respir Crit Care Med* 2002; 165:B36.
50. Wooldridge JL, Deutsch GH, Sontag MK, Osberg I, Chase DR, Sildoff PE, Wagener JS, Accurso FJ. The nitric oxide pathway in infants and young children with cystic fibrosis. *Pediatr Pulmonol* 2002: suppl. in press.
51. VanDevanter DR, Wagener JS, Konstan MW, Smith AL, Yu X. Implications of unique adverse events for clinical trials conducted in asymptomatic CF subjects. *Pediatr Pulmonol* 2003:suppl.
52. Konstan MW, Wagener JS, Hilliard KA, Kowalczyk TH, Hyatt SL, Fink TL, Gedeon CR, Oette SM, Payne JM, Muhammad O, Klepcyk P, Peischl A, Davis PB, Moen RC, Cooper MJ. Single dose escalation study to evaluate safety of nasal administration of CFTR001 gene transfer vector to subjects with cystic fibrosis. *Pediatr Pulmonol* 2004: suppl.
53. McMullen A, Pasta D, Frederick P, Wagener JS, and the investigators and coordinators for the epidemiologic study of cystic fibrosis. Intensity of therapies during and following pregnancy in cystic fibrosis patients. *Pediatr Pulmonol* 2004: suppl.
54. Accurso FJ, Sagel SD, Sontag MK, Wagener JS. Anti-inflammatory endpoints in cystic fibrosis: Lessons from clinical trials. *Pediatr Pulmonol* 2004: suppl.
55. Sagel SD, Emerson J, Wagener JS, Gibson R. Inflammation in pseudomonas infected infants with CF. *Pediatr Pulmonol* 2004: suppl.

56. Konstan MW, Wagener JS, Silva SJ, Pasta DJ, Morgan WJ. Clinical use of dornase alfa is associated with a slower rate of lung function decline in patients with cystic fibrosis. *Pediatr Pulmonol* 2006: suppl.
57. Moskowitz SM, Silva SJ, Mayer-Hamblett N, Pasta DJ, Mink DR, Wagener JS, Konstan MW, Morgan WJ. Inhaled antibiotic use among north American cystic fibrosis patients. *Am J Respir Crit Care Med* 2007: suppl.
58. Wagener JS, VanDevanter DR, Rasouliyan LH, Murphy TM, Morgan WJ, Ren CL, Konstan MW. Change in the clinical appearance of the cystic fibrosis patient population over time. *Pediatr Pulmonol* 2007: suppl.
59. VandenBranden SL, McMullen A, Silva SJ, Konstan MW, Wagener JS, Morgan WJ, Schechter MS, Watts KD, Pasta DJ, McColley SA. Characteristic changes in lung function decline from adolescence to young adulthood. *Pediatr Pulmonol* 2007: suppl.
60. Wagener J, Rasouliyan L, Pasta D, Mabie J, Morgan W, Konstan M. Practice patterns for treating respiratory exacerbations in cystic fibrosis. *Pediatr Pulmonol* 2008: suppl.
61. Sawicki G, Rasouliyan L, Pasta D, Wagener J, McColley S, Quittner A. Longitudinal Assessment of Changes in Health Status and Health-Related Quality of Life in Cystic Fibrosis. *Pediatr Pulmonol* 2008: suppl.
62. Liou T, Elkin D, Pasta D, Jacobs J, Konstan M, Morgan W, Wagener J. Year to year changes in lung function in individuals with cystic fibrosis. *Pediatr Pulmonol* 2008: suppl.
63. Konstan M, Rasouliyan L, Pasta D, Morgan W, Wagener J. Trends in the use of routine therapies in cystic fibrosis: 1995-2005. *Pediatr Pulmonol* 2008: suppl.
64. Wagener J, VanDevanter D, Pasta D, Elkin E, Jacobs J, Morgan W, Konstan M. A tool for predicting risk of future lung function decline in cystic fibrosis patients. *Am J Respir Crit Care Med* 2009: suppl.
65. Konstan MW, Rasouliyan L, Pasta DJ, Yegin A, Jacobs JR, Liou TG, Wagener JS. Risk factors for rate of decline in FEV1 in adults with CF. *Pediatr Pulmonol* 2009: suppl.
66. Konstan M, Silva S, Wagener J, Pasta D, Yegin A, VanDevanter D. Rate of lung function decline as an outcome for randomized controlled trials in cystic fibrosis. *Pediatr Pulmonol* 2009: suppl.
67. Wagener J, McColley SA, Elkin E, Yegin A, Pasta D, Liou T, Morgan W, Konstan M. Evaluating cystic fibrosis care site outcomes with single-year versus longitudinal data. *Pediatr Pulmonol* 2009: suppl.
68. Sontag MK, Accurso FJ, Wagener JS, Zemanick E, Sagel SD. Newborn screening for Cystic Fibrosis: IRT is lower in Infants with meconium ileus. Proceedings of the Newborn Screening and Genetics Testing Symposium 2011.
69. Flume P, Wainwright C, Tullis E, Rodriguez S, Davies J, Wagener J. Pulmonary exacerbations in patients with cystic fibrosis and the *G551D-CFTR* mutation treated with ivacaftor. European Cystic Fibrosis Society Conference 2013.
70. Fink A, Alexander E, Marshall B, Wagener J. Epidemiology and phenotypic variability of US patients with cystic fibrosis and the R117H mutation. *Pediatr Pulmonol* 2013: suppl.

71. Sawicki GS, McKone E, Pasta DJ, Wagener J, Johnson C, Konstan MW. The effect of ivacaftor on the rate of lung function decline in CF patients with a *G551D-CFTR* mutation. European Cystic Fibrosis Society Conference 2014.
72. Sawicki GS, McKone EF, Pasta DJ, Wagener JS, Johnson CA, Millar SJ, Konstan MW. The effect of ivacaftor on weight over three years in patients with CF and a *G551D-CFTR* mutation. North American Cystic Fibrosis Conference 2014.
73. Morgan WJ, Wagener J, Pasta DJ, Millar S, Konstan MW. Antibiotics and hospitalization are associated with improved recovery after acute decline in FEV₁ in patients with CF. North American Cystic Fibrosis Conference 2014
74. McKone EF, Sawicki GS, Miller SJ, Pasta DJ, Rubin JL, Johnson C, Konstan MW, Wagener JS. Improved rate of decline in percent predicted FEV₁ is not associated with acute improvement in percent predicted FEV₁ in patients with cystic fibrosis treated with ivacaftor. North American Cystic Fibrosis Conference 2015.

XIV. OTHER

A. Formal Study to Improve Teaching Abilities

1. Medical Education Workshop, Department of Pediatrics and School of Education 1984
2. ACLS Instructors Course 1986
3. Medical Education Workshop, "Presenting Research Results at Seminars and National Meetings" 1987
4. Newborn Resuscitation National Affiliate Faculty Course 1988
5. Medical Education Workshop, "Teaching During Attending Rounds" 1989
6. Medical Ethics Graduate Reading Course 1990
7. Medical Spanish 1994
8. Evidence Based Medicine, Cochrane collaboration course 1999
9. Protecting Study Volunteers in Research (101) 2000
10. Protecting Study Volunteers in Research (201) 2000
11. Protecting Study Volunteers in Research (FDA and OHRP) 2001
12. Protecting Study Volunteers in Research (FDA and HIPPA) 2002
13. Protection of Human Research Subjects, CITI course 2005
14. New Training Program Directors, ACGME course 2008
15. Protection of Human Research Subjects, CITI course 2008
16. Teaching in the clinical setting, Association of Medical Educators 2009
17. OSKE testing in Pediatrics, University of Dublin 2011
18. Certified Interpretive Guide, National Association of Interpreters 2015

B. Teaching Responsibilities

- | | |
|--|-----------|
| Pediatric Pulmonary Fellowship Advisor | 1983-2013 |
| 2nd Year Medical Student Clinical Diagnosis (Instructor) | 1990-95 |

Curriculum Vitae
Jeffrey Scott Wagener, MD

3rd Year Medical Student Advisor	1992-99
Resident Advisor	1994-05
Child Health Associate Program (lecturer)	1995-2012
Human Genetics course (lecturer)	1998-2006
Pediatric Pulmonary Fellows clinic director	2007-13
Pediatric Pulmonary Fellows clinic attending	2014-present

C. Research and Clinical Fellow Trainees

(b) (6)



(b) (6)



D. Invited Regional/National/International Lectures

1. Treatment of Croup and Epiglottitis. Arizona Society for Respiratory Therapy; Tucson, AZ, September 1980.
2. Drowning and Near Drowning. Crisis in Emergency Care Conference; Tucson, AZ, March 1981.
3. Bronchopulmonary Dysplasia in Children. Worcester City Hospital Continuing Medical Education; Worcester, MA, January 1982.
4. Respiratory Infections in Children. Minowa County Medical Society Continuing Medical Education; Muscatine, IA, October 1983.
5. Recent Advances in Cystic Fibrosis. Iowa CF Foundation Annual Meeting; Des Moines, IA, February 1984.
6. Airway Emergencies in Children. Iowa Family Physician Refresher Course; Iowa City, IA, March 1984.
7. Pediatric Respiratory Cases. Iowa Medical Society Annual Meeting, Iowa City, IA, April 1984.
8. New Trends in Asthma Therapy. Hawkeye Institute of Technology, Cedar Rapids, IA, September 1984.
9. Infant Apnea. Fourth Annual Iowa Pulmonary Seminar - Respiratory Therapy; Iowa City, IA, September 1984.
10. Assessing the Respiratory System in Children. Annual Iowa Nurse Refresher Seminar, Iowa City, IA, March 1985.
11. History and Care in Cystic Fibrosis. Pediatrics Grand Rounds, Dubuque, IA, March 1985.
12. New Aspects in Obstructive Airway Disease Therapy. Quad-Cities Physician Practice Association; Moline, IL, April 1985.
13. Home Oxygen and Tracheostomy Care for Infants. American Thoracic Society, May 1985.
14. Mechanical Ventilation Techniques for Infants and Young Children. Fall Pulmonary Seminar, Iowa City, IA, September 1985.
15. History and Care in Cystic Fibrosis. Sioux City Pediatrics Group; Sioux City, IA, November 1985.
16. Epiglottitis in Children. Davenport Family Practice Program; Davenport, IA, December 1985.
17. Managing Lower Airway Obstruction. Blank Children's Hospital Grand Rounds; Des Moines, IA, December 1985.
18. Epiglottitis and Croup. Sioux City Pediatrics Group; Sioux City, IA, April 1986.
19. Managing Asthma. Mercy Hospital; Cedar Rapids, IA, April 1986.
20. Lower Respiratory Tract Illness in Children. College of Nursing; Iowa City, IA, April 1986.
21. Bronchopulmonary Dysplasia. Blank Children's Hospital Grand Rounds; Des Moines, IA, April 1986.
22. Infant Apnea. Davenport Family Practice Program; Davenport, IA, May 1986.
23. Managing Upper Airway Obstruction in Children. Dubuque Pediatrics Group; Dubuque,

- IA, May 1986.
24. Tracheostomy in Children. Fall Pulmonary Seminar; Iowa City, IA, September 1986.
 25. Pediatric Respiratory Disease. Iowa Family Physician Refresher Course; Iowa City, IA, October 1986.
 26. Anesthetic Management for the Child with Asthma. University of Iowa Anesthesiology Conference; December 1986.
 27. Managing Children with Bronchopulmonary Dysplasia. University of Iowa Department of Nursing; December 1986.
 28. Cystic Fibrosis - New Genes and New Lungs. Iowa Cystic Fibrosis Foundation; Des Moines, IA, April 1987.
 29. Convalescent Care for Infants with Chronic Pulmonary Problems. Great Plains Conference on Perinatal Medicine; Ames, IA, April 1987.
 30. National Tele-session on Current Concepts in Asthma Management. Fisons Corporation; April 1987.
 31. Childhood Asthma: The Past and Future. American Lung Association National Conference; May 1987.
 32. Research in Childhood Asthma. American Thoracic Society, symposium moderator, May 1987.
 33. Pediatric Emergencies. Kirkwood Community College; Cedar Rapids, IA, June 1987.
 34. Post-NICU Care. Iowa State Neonatal Seminar; Ames, IA, September 1987.
 35. Pediatric Emergencies. Annual Iowa Emergency Medicine Conference; Cedar Rapids, IA, October 1987.
 36. Oximetry and Home Monitoring in BPD. Pediatric Postgraduate Conference; Iowa City, IA, October 1987.
 37. Current Trends in Pharmacotherapy for Cystic Fibrosis. University of Iowa Pharmacy Department; November 1987.
 38. Bronchiolitis. Davenport Family Practice Program; Davenport, IA, January 1988.
 39. New Trends in Infant Ventilation. Davenport St. Lukes Pulmonary Department CME; Davenport, IA, January 1988.
 40. Pediatric Resuscitation. University of Iowa Family Practice Program; January 1988.
 41. Asthma Management. University of Otago, Wellington, New Zealand; February 1988.
 42. Lung Growth and Pulmonary Perfusion. University of Melbourne, Melbourne, Australia; March 1988.
 43. Cystic Fibrosis- Recent Advances. Western Australia Cystic Fibrosis Association, Perth, Australia; March 1988.
 44. Asthma: An American Approach. University of Western Australia, Perth, Australia; March 1988.
 45. Lung Growth and Pulmonary Perfusion. University of Western Australia, Perth, Australia; March 1988.
 46. Surgically Important Pediatric Pulmonary Problems. Cardiothoracic Surgery Rounds; Iowa City, IA, June 1988.

47. Croup and Epiglottitis. Annual Iowa Physician Assistant Society Meeting; Iowa City, IA, August 1988.
48. Multidisciplinary Care in BPD. Annual Iowa Respiratory Therapy Conference; Iowa City, IA, September 1988.
49. Home Care of the Technology Dependent Child. Iowa Pediatric Postgraduate Conference; seminar moderator, November 1988.
50. Respiratory Emergencies: Upper Airway, Lower Airway, and Bronchiolitis. Kansas City Annual Pediatric CME; Kansas City, KS, November 1988.
51. Therapy for ARDS. Iowa Pulmonary-Immunology Seminar; Iowa City, IA, November 1988.
52. Bronchodilators and the Treatment of Bronchospasm. University of Iowa Anesthesia Conference; December 1988.
53. Respiratory Emergencies in Children. Mercy Hospital Family Practice Grand Rounds, Iowa City, IA, February 1989.
54. Respiratory Emergencies in Children. St. Luke's Hospital Family Practice Grand Rounds, Cedar Rapids; IA, February 1989.
55. Stridor in Children. Iowa Family Practice Refresher Course, Iowa City; IA, March 1989.
56. Treatment of Chronic Asthma. Mercy Hospital Family Practice Grand Rounds, Iowa City; IA, April 1989.
57. Bronchopulmonary Dysplasia. American Thoracic Society; symposium moderator, May 1989.
58. Bronchopulmonary Dysplasia. Iowa Perinatal Conference, Ames; IA, September 1989.
59. Thoracic Cage Abnormalities. Annual Iowa Respiratory Therapy Conference; Iowa City, IA, September 1989.
60. CF: Clinical Manifestations and Challenges. CF Research Development Program Retreat; Iowa City, IA, September 1989.
61. Near Drowning. Iowa Emergency Medical Conference, Cedar Rapids; IA, November 1989.
62. Heart-Lung Interactions. University of Iowa Cardiology Conference; December 1989.
63. Croup and Epiglottitis. Denver Children's Hospital; Denver, CO, December 1989.
64. Child with Chronic Cough and Infections. Broadlawns Family Practice Grand Rounds, Des Moines; IA, February 1990.
65. Respiratory Disease in Children. Muscatine General Hospital, Muscatine; IA, February 1990.
66. Children with Chronic and Recurrent Cough. Davenport Family Practice Grand Rounds; Davenport, IA, April 1990.
67. Pulmonary Assessment in the Neonatal and Pediatric Patients. Colorado Society for Respiratory Care; Denver, CO, February 1991.
68. Croup and Epiglottitis - Controversies and Care Annual Family Practice Review, University of Colorado, June 1991.
69. Pulmonary Function Interpretation, The Children's Hospital Respiratory Therapy Conference, Denver, CO, September 1991.

70. Respiratory Emergencies in Children, Anesthesia Grand Rounds, University of Kansas, October 1991.
71. Channels, Genes, and Cystic Fibrosis, Pediatrics Grand Rounds, University of Kansas, October 1991.
72. Managing Croup and Epiglottitis, Family Practice Conference, University of Kansas, October 1991.
73. Long Term Management of BPD, Pediatrics Grand Rounds, University of Kansas, October 1991.
74. Channels, Genes, and Cystic Fibrosis, Grand Rounds, National Jewish Hospital, Denver, CO, December, 1991.
75. RSV Bronchiolitis, Winter Pulmonary Symposium, Grand Junction, CO, January 1992.
76. Asthma Management in Children, Winter Pulmonary Symposium, Grand Junction, CO, January 1992.
77. Common Respiratory Diseases in Children, Child Health Associate Program, University of Colorado, April 1992.
78. Evaluation of the Wheezing Patient, Respiratory Therapy Continuing Education, The Children's Hospital, Denver, CO, May 1992.
79. RSV Bronchiolitis. Annual Montana Pediatrics Society Meeting, Big Sky, MT, September 1992.
80. Asthma: Uncle Sam's Protocols. Annual Montana Pediatrics Society Meeting, Big Sky, MT, September 1992.
81. Channels, Genes, and Cystic Fibrosis. Annual Montana Pediatrics Society Meeting, Big Sky, MT, September 1992.
82. Where there is Smoke; There is Lung Disease. Iowa Emergency Medicine Conference, Cedar Rapids, IA, October 1992.
83. Acute Asthma; Keep it Simple. Iowa Emergency Medicine Conference, Cedar Rapids, IA, October 1992.
84. Asthma Management: Uncle Sam's Protocols. Fitzsimons Pediatrics Conference. Denver, CO, October 1992.
85. Common Childhood Respiratory Disease, Respiratory Therapy Continuing Education, Children's Hospital, Denver, CO, April 1993.
86. Steroid Management for Childhood Asthma. American Thoracic Society. Boston, MA, May 1994.
87. Cystic Fibrosis Update. Uniform Services Meeting. San Francisco, CA, March 1995.
88. Managing Chronic Lung Disease in Children. Uniform Services Meeting. San Francisco, CA, March 1995.
89. Steroid Management for Childhood Asthma (Symposium). American Thoracic Society. Seattle, WA, May 1995.
90. Asthma Management in Children (Grand Rounds). Evan's Army Hospital, Colorado Springs, CO, August 1995.
91. Early Pulmonary Treatment in Cystic Fibrosis. North American Cystic Fibrosis

- Conference. Dallas, TX, October 1995.
92. Newborn Screening for Cystic Fibrosis. Memorial Hospital. Colorado Springs, CO, April 1995.
 93. Asthma in Children. Montana Respiratory Therapy Convention. Bozeman, MT, May 1996.
 94. Cystic Fibrosis and Inflammation. Montana Respiratory Therapy Convention. Bozeman, MT, May 1996.
 95. Inflammation in Infants with Cystic Fibrosis. 2nd International Pediatric Pulmonary Conference. Nice, France, June 1996.
 96. Inhaled Steroids in Cystic Fibrosis. International Cystic Fibrosis Conference. Jerusalem, Israel, June 1996.
 97. Research in Cystic Fibrosis - 1997 (Research Seminar). University of Canterbury, Christchurch, New Zealand, March 1997.
 98. Channels, Genes, and Cystic Fibrosis (Grand Rounds). Christchurch Hospital, Christchurch, New Zealand, April 1997.
 99. Channels, Genes, and Cystic Fibrosis (Pediatric Grand Rounds). Otago University Dunedin, New Zealand, May 1997.
 100. Acute Respiratory Illness in Children. American Academy of Pediatrics CME. Washington, DC, June 1997.
 101. Bronchiolitis: Is Oxygen all That is Needed? American Academy of Pediatrics CME, Washington, DC, June 1997.
 102. Anti-inflammatory Therapy of Asthma: What's New? American Academy of Pediatrics CME, Washington, DC, June 1997.
 103. Chronic Cough: What to do and When to Refer. American Academy of Pediatrics CME, Washington, DC, June 1997.
 104. Managing Asthma. Clinica Campasina, Denver, CO, April 1998.
 105. New cases of pseudomonas aeruginosa: Risk factors and outcomes. North American Cystic Fibrosis Conference, Montreal, Canada, October 1998.
 106. Taking care of the evolving lung disease in cystic fibrosis. CF Center annual meeting, Souix Falls, SD, May 1999.
 107. Clearing the airway as the cystic fibrosis patient grows up. South Dakota Respiratory Therapy Conference, Souix Falls, SD, May 1999.
 108. CF Care: The Future. Annual Parents Meeting, Souix Falls, SD, May 1999.
 109. CF Care: The Benefits of Early Diagnosis and Aggressive Therapy. Wichita, KS, June 1999.
 110. The CFF TDN. Four Corners CF Meeting, Salt Lake City, UT, June 1999.
 111. The Benefits of Early Diagnosis and Aggressive Therapy. CF Roundtable, San Francisco, CA, August 1999.
 112. CF Care: The Future. Annual Parents Meeting, Wichita, KS, September 1999.
 113. Cystic Fibrosis Debate: Ibuprofen and Pseudomonas. (moderator) North American Cystic Fibrosis Conference, Seattle, WA, October 1999.
 114. Nutrition and Pulmonary Function in Cystic Fibrosis. Four Corners CF Meeting,

- Breckenridge, CO, June 2000.
115. Newborn Screening for Cystic Fibrosis. Malaga conference on Numology, Malaga, Spain, November 2000.
 116. Early Pulmonary Disease in Cystic Fibrosis. Malaga conference on Numology, Malaga, Spain, November 2000.
 117. Cystic Fibrosis Debate: Newborn screening and Transplant infections. (moderator) North American Cystic Fibrosis Conference, Baltimore, MD, November 2000.
 118. CF Clinical Overview: What happens when lung defenses fail? North American Cystic Fibrosis Conference, Baltimore, MD, November 2000.
 119. Treating CF patients with mild lung disease. Texas CF Consortium, San Antonio, TX, May 2001.
 120. Treating CF patients with mild lung disease. Mountain West CF Consortium, Albuquerque, NM, June 2001.
 121. Treating CF patients with mild lung disease. Pacific Northwest CF Consortium, Seattle, WA, June 2001.
 122. Onset and etiology of airway inflammation in CF. European Respiratory Society Meeting, Berlin, Germany, September 2001.
 123. Early inflammation and infection in the CF lung. North American Cystic Fibrosis Conference, Orlando, FL, October 2001.
 124. Treating CF patients with mild lung disease. North American Cystic Fibrosis Conference, Orlando, FL, October 2001.
 125. Bronchoscopy in CF patients. North American Cystic Fibrosis Conference, Orlando, FL, October 2001.
 126. Newborn screening for CF. Boston Children's Hospital, Boston, MA, March 2002.
 127. Treating CF patients with mild lung disease. Boston Pulmonary Meeting, Boston, MA, March 2002.
 128. ESCF data and clinical implications. Midwest Cystic Fibrosis Consortium Meeting, St. Louis, MO, April 2002.
 129. Evaluation and management of CF lung disease in infants. American Thoracic Society, Atlanta, GA, May 2002.
 130. Pulmonary function in infants with CF. American Thoracic Society (moderator), Atlanta, GA, May 2002.
 131. Treating CF patients with mild lung disease. New York City Pulmonary Meeting, New York, NY, June 2002.
 132. Respiratory therapy for Cystic Fibrosis. Respiratory Care Symposium, Keystone, CO, August 2002.
 133. Risk factors for Pseudomonas acquisition. North American CF Meeting, New Orleans, LA, October 2002.
 134. Cystic Fibrosis clinical overview: What happens when lung defenses fail. North American CF Meeting, New Orleans, LA, October 2002.
 135. Therapy trends in Cystic Fibrosis. North American CF Meeting, New Orleans, LA, October

- 2002.
136. Pre-symptomatic CF in an infant and child. ACCP/AAP Pulmonary Conference, Scottsdale, AZ, March 2003.
 137. Five best articles in CF. ACCP/AAP Pulmonary Conference, Scottsdale, AZ, March 2003.
 138. End-points of asthma treatment. ACCP/AAP Pulmonary Conference, Scottsdale, AZ, March 2003.
 139. Understanding CF: Knowledge gained through newborn screening. Grand Rounds, New York Medical College, Valhalla, NY, April 2003.
 140. Cystic Fibrosis: The future begins now. Long Island Jewish Medical Center, Long Island, NY, April 2003.
 141. Inflammatory changes in CF and Asthma. Robert Wood Johnson Medical Center, NJ, April 2003.
 142. Allergic bronchopulmonary aspergillosis in CF. ATS National Conference, Seattle, WA, May 2003.
 143. Cystic Fibrosis management, A-Z. American Thoracic Society international conference. May 2003.
 144. Airway inflammation: Lessons learned from clinical studies. Williamsburg Conference, Williamsburg, VA, June 2003.
 145. Epidemiologic Study of CF. Salt Lake City, UT, June 2003.
 146. Pathophysiology of Cystic Fibrosis Lung Disease, Brazil CF Conference, Sao Paulo, Brazil, July 2003.
 147. Diagnosing lung disease in Cystic Fibrosis, Brazil CF Conference, Sao Paulo, Brazil, July 2003.
 148. Treating CF patients with mild lung disease. Brazil CF conference, Sao Paulo, Brazil, July 2003.
 149. Cystic Fibrosis pulmonary pathophysiology. NACF Conference, Anaheim, CA, Oct 2003.
 150. Cystic Fibrosis lung function testing. NACF Conference, Anaheim, CA, Oct 2003.
 151. Treating and monitoring Cystic Fibrosis patients with early lung disease. NACF Conference, Anaheim, CA, Oct 2003.
 152. Implementing new respiratory therapy equipment disinfection techniques for CF patients. NACF Conference, Anaheim, CA, Oct 2003.
 153. Respiratory disease in children. Child Health Associate Program, Denver, CO, Jan 2004.
 154. Channels, genes, and Cystic Fibrosis. Molecular, cellular, and developmental biology course, University of Colorado, Boulder, CO, Feb 2004
 155. Cystic fibrosis treatment practice guidelines: Pulmonary. Prime Quality Improvement conference, Los Angeles, CA, March 2004.
 156. Early *Pseudomonas aeruginosa* colonization in cystic fibrosis. South Central Cystic Fibrosis consortium, Houston, TX, April 2004.
 157. Cystic fibrosis: Knowledge gained through newborn screening. South Central Cystic Fibrosis consortium, Houston, TX, April 2004.
 158. Diagnosing and treating lung infection in the CF patient with mild lung disease. Milwaukee

- Cystic Fibrosis center, Milwaukee, WI, April 2004.
159. Newborn screening for cystic fibrosis. Conference facilitator, Latin American Congress on Cystic Fibrosis, Rio de Janeiro, Brazil, April 2004.
 160. Dornase alpha in young children: Efficacy and safety. Latin American Congress on Cystic Fibrosis, Rio de Janeiro, Brazil, April 2004.
 161. Diabetes in cystic fibrosis. Latin American Congress on Cystic Fibrosis, Rio de Janeiro, Brazil, April 2004.
 162. Adults with cystic fibrosis. Latin American Congress on Cystic Fibrosis, Rio de Janeiro, Brazil, April 2004.
 163. Practical management of pneumothorax. Latin American Congress on Cystic Fibrosis, Rio de Janeiro, Brazil, April 2004.
 164. Early intervention in cystic fibrosis. Latin American Congress on Cystic Fibrosis, Rio de Janeiro, Brazil, April 2004.
 165. Asthma: A stepwise approach. Wyoming Medical Society, June 2004.
 166. Infection control for cystic fibrosis. North American CF Conference, October 2004.
 167. Quality improvement in cystic fibrosis. Montana CF Program, October 2004.
 168. Airway inflammation in cystic fibrosis: Lessons learned from clinical studies. Nikki May visiting lecture, Melbourne, Australia, November 2004.
 169. Early pseudomonas intervention in cystic fibrosis, Munich, Germany, February 2005.
 170. Understanding cystic fibrosis: Knowledge gained from newborn screening. Montana Thoracic Society, 2005.
 171. Cystic Fibrosis: The future begins now. Montana Thoracic Society, 2005
 172. Antibiotic resistance in cystic fibrosis. Mountain West CF Conference, Phoenix, June 2005.
 173. Pediatric pneumonia. Kaiser Pediatric Seminar, Denver, July 2005.
 174. Complicated pneumonias in children. Masters in Pediatrics Conference, Miami, Jan 2006
 175. Airway inflammation in CF. Masters in Pediatrics Conference, Miami, Jan 2006.
 176. Common respiratory disorders. Masters in Pediatrics Conference, Miami, Jan 2006.
 177. Hypertonic saline vs. dornase alpha. 1st Brazilian CF Conference, Sao Paulo, April 2006.
 178. Treating exacerbations in CF. 1st Brazilian CF Conference, Sao Paulo, April 2006.
 179. Starting dornase alpha. 1st Brazilian CF Conference, Sao Paulo, April 2006.
 180. Pseudomonas treatment strategies. 1st Brazilian CF Conference, Sao Paulo, April 2006.
 181. Mild CF lung disease. 1st Brazilian CF Conference, Sao Paulo, April 2006.
 182. Cystic Fibrosis: The future begins now. Orlando Cystic Fibrosis Center, 2006.
 183. Risk for PFT decline in Cystic Fibrosis. Sydney, Melbourne, Brisbane, and Adelaide, Australia, May 2007.
 184. Cystic Fibrosis: The future begins now. Nebraska Cystic Fibrosis Center, Omaha, June 2007.
 185. Treating CF lung disease. Mexico Thoracic Society, Ixtapa, Mexico, March 2008.
 186. Clinical guidelines in CF. Mexico Thoracic Society, Ixtapa, Mexico, March 2008.
 187. Rate of decline in CF lung disease. University of North Carolina, April 2008.
 188. Promising new therapies in CF. Italian CF Foundation, Verona, Italy, May 2008.

189. Infant pulmonary function testing. International Pediatric Pulmonary Conference, Mexico City, Mexico, September 2008.
190. Promising clinical trials in CF. International Pediatric Pulmonary Conference, Mexico City, Mexico, September 2008.
191. Early treatment of Pseudomonas infection in CF. International Pediatric Pulmonary Conference, Mexico City, Mexico, September 2008.
192. Standard care for CF lung disease. International Pediatric Pulmonary Conference, Mexico City, Mexico, September 2008.
193. Interstitial lung disease in children. International Pediatric Pulmonary Conference, Mexico City, Mexico, September 2008.
194. Practice patterns for treating respiratory exacerbations in cystic fibrosis. NACFC, Orlando, FL, October 2008.
195. New advances in asthma care for children. Michigan Thoracic Society Conference, Ann Arbor, MI, April 2009.
196. A Tool for Predicting Risk of Future Lung Function Decline in Cystic Fibrosis Patients. ATS conference, San Diego, CA, May 2009.
197. Cystic Fibrosis: Early intervention in paediatrics. European Cystic Fibrosis Conference, Brest, France, June 2009.
198. Cystic Fibrosis lung disease: Rethinking the at-risk patient. St. Petersburg, FL, July 2009.
199. Cystic Fibrosis lung disease: Rethinking the at-risk patient. Pulmonary Rounds, Charleston, SC, September 2009.
200. Cystic Fibrosis lung disease: Rethinking the at-risk patient. Pulmonary Rounds, Boston, MA, September 2009.
201. Cystic Fibrosis: The future begins now. CF parents night, Miami, FL, October 2009.
202. Cystic Fibrosis: Finding the cure. Pediatric Grand Rounds, Miami, FL, October 2009.
203. Risk factors for progression of CF lung disease. Pulmonary research conference, Miami, FL, October 2009
204. Cystic Fibrosis lung disease: Rethinking the at-risk patient. Pulmonary Rounds, Miami, FL, October 2009.
205. Treating respiratory exacerbations in CF. North American CF Conference, Minneapolis, MN, October 2009.
206. Cystic Fibrosis: Finding the cure. Pediatric Grand Rounds, Canterbury University, Christchurch, New Zealand, December 2009.
207. Cystic Fibrosis: Genetic based therapy. Pediatric Journal Club, Children's University Hospital, Dublin, Ireland, January 2011.
208. Pulmonary function testing in children. Pediatric Education Meeting, Children's University Hospital, Dublin, Ireland, March 2011.
209. Risk of pseudomonas acquisition in CF. Brazilian Cystic Fibrosis Conference, Florianopolis, Brazil, May 2012.
210. Risk factors for lung function decline in CF. Brazilian Cystic Fibrosis Conference, Florianopolis, Brazil, May 2012.

211. Early intervention in CF. Brazilian Cystic Fibrosis Conference, Florinopolis, Brazil, May 2012.
212. Dornase alfa: benefits from a unique mechanism of action. Brazilian Cystic Fibrosis Conference, Florinopolis, Brazil, May 2012.
213. Cystic Fibrosis. ACCP/AAP Pulmonary Board review course, Las Vegas, August 2012.
214. Gastroesophageal reflux and aspiration syndromes. ACCP/AAP Pulmonary Board review course, Las Vegas, August 2012.
215. Neuromuscular disease. ACCP/AAP Pulmonary Board review course, Las Vegas, August 2012.
216. Channels, genes, and Cystic Fibrosis. Pediatric Grand Rounds, SUNY, Brooklyn, September 2013.
217. Epidemiology and phenotypic variability of US patients with cystic fibrosis and the R117H mutation. North American Cystic Fibrosis Conference, Salt Lake City, October 2013.